Softwr

Research · head to head

Form Bio vs Greenphire

Form Bio logo

Form Bio

Research

Computational platform for cell and gene therapy design and manufacturability

From
On request
Rated
-
Greenphire logo

Greenphire

Research

Clinical trial participant payments, reimbursement and travel, now part of Suvoda

From
On request
Rated
-

The short version

  • Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; Greenphire the standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • They diverge on capability: Form Bio covers FormManufacturing, Greenphire covers ClinCard.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Form Bio and Greenphire actually diverge.

Attributes where Form Bio and Greenphire differ
AttributeForm BioGreenphire
PlatformsWeb, CloudWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Form Bio

  • FormManufacturing
  • Payload design optimisation
  • Genome integrity analysis
  • Manufacturability prediction
  • In silico workflows
  • Scale-up monitoring
  • Cell and gene therapy focus
  • Collaboration

Only in Greenphire

  • ClinCard
  • Direct to bank payment
  • Expense reimbursement
  • Travel and logistics
  • Site payments
  • Budgeting and benchmarking
  • Tax handling

What people use each for

The jobs each tool is most often brought in to do.

Form Bio

  • A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Greenphire
  • A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Greenphire
  • A CDMO characterising what a client construct actually produces against what was specifiednot Greenphire
  • A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Greenphire

Greenphire

  • A global Phase III trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payablenot Form Bio
  • A decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodationnot Form Bio
  • A trial in a population where slow reimbursement drives dropout and same day payment materially helps retentionnot Form Bio
  • A sponsor that wants site payment milestones and participant payments handled by one vendor rather than twonot Form Bio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Form Bio

  • The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
  • The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
  • No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
  • This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
  • Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.

Greenphire

  • The standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • Nothing is published on price, and the typical shape of a platform fee plus per participant and per transaction charges means the cost of a trial is not knowable until enrolment is known.
  • Payment method availability varies sharply by country, so a global protocol may end up with card payments in some regions and slow manual processes in others, which undermines the retention argument that justified the purchase.
  • Sites bear the administrative work of enrolling participants and triggering payments but are not the buyer, so adoption depends on the sponsor mandating it and site resistance is a real implementation risk.
  • Participant payments create tax reporting obligations that differ per jurisdiction, and the tooling helps but does not remove sponsor liability, so legal and finance review is required in every country the trial runs in.

Pricing, plan by plan

Form Bio

On request
  • FormManufacturing$undefined/year
    • Pricing only through a sales process
    • Scoped per therapeutic programme rather than per seat
    • AAV-focused offering at launch

Greenphire

On request
  • Greenphire Patient Payments$undefined/year
    • Priced per study through a sales process
    • Typically a platform fee plus per participant and per transaction charges
    • Funding of the payment float is separate from the software fee

Which should you pick?

Choose Form Bio if

  • You need formmanufacturing.
  • You work on Web, Cloud.
  • You also want payload design optimisation.

Choose Greenphire if

  • You need clincard.
  • You work on Web, iOS, Android.
  • You also want direct to bank payment.

Questions people ask

Is Form Bio or Greenphire better?
Neither clearly leads. Form Bio starts at On request and Greenphire at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Form Bio or Greenphire?
Form Bio starts at On request and Greenphire at On request.
Does Form Bio or Greenphire run on more platforms?
Form Bio runs on Web, Cloud. Greenphire runs on Web, iOS, Android.
What is Form Bio best used for?
Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what Greenphire is typically brought in for.
What can Form Bio do that Greenphire cannot?
Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. Greenphire covers ClinCard, Direct to bank payment, Expense reimbursement, Travel and logistics.

Answered from the vendors’ own pages

Form Bio: What does Form Bio sell now?

FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.

Greenphire: Is Greenphire still sold?

Yes, as Greenphire Patient Payments on the Suvoda platform. The independent website and social presence have been consolidated into Suvoda.

Form Bio: Is it still a general bioinformatics platform?

No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.

Greenphire: What is ClinCard?

The reloadable debit card Greenphire issues to participants. Greenphire Patient Payments was formerly known as ClinCard.

Form Bio: Where did the company come from?

It spun out of Colossal Biosciences in 2022.

Greenphire: Does it publish pricing?

No. Pricing is per study and quoted through sales, and funding the payments themselves is separate from the software fee.

Form Bio: Is pricing published?

No. Engagements are scoped per programme through a sales process.

Greenphire: Can it pay participants outside the United States?

Yes, in more than thirty currencies, but the available payment method depends on the country.

Share

Related pages

Other head to heads